CompletedPhase 3NCT05664750
Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus
Studying Tetanus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
- Principal Investigator
- Chuanlin Wang, MD, MDPeking University People's Hospital
- Intervention
- TNM002(drug)
- Enrollment
- 675 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2023
Study locations (28)
- Hefei First People's Hospital, Hefei, Anhui, China
- The Second Hospital of Anhui Medical University, Hefei, Anhui, China
- Peking University First Hospital, Beijing, Beijing Municipality, China
- Peking University People's Hospital, Beijing, Beijing Municipality, China
- Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing Municipality, China
- The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China
- The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
- Guangzhou First People's Hospital, Guangzhou, Guangdong, China
- Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
- The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
- Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
- Liuzhou Worker's Hospital - Fourth Affiliated Hospital of Guangxi Medical University, Liuchow, Guangxi, China
- Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, China
- Hainan General Hospital, Haikou, Hainan, China
- +13 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05664750 on ClinicalTrials.govOther trials for Tetanus
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07149454Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Anti-Tetanus Toxin Monoclonal Antibody InjectionLanzhou Institute of Biological Products Co., Ltd
- RECRUITINGNCT07107932A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following InjuryZhuhai Trinomab Pharmaceutical Co., Ltd.
- RECRUITINGPHASE3NCT06635798A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 InjectionGenrix (Shanghai) Biopharmaceutical Co., Ltd.